Biblio

Author [ Title(Desc)] Type Year
Filters: Author is Xu, Lan-Ping  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Ma, R., Huang, X.-J., Xu, L.-P., Liu, K.-Y., Zhang, X.-H., Yan, C.-H., Han, W., Wang, F.-R., Chen, Y.-H., Chen, H., et al. (2019). Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies.Biol Blood Marrow Transplant.
Chen, Y., Fu, W.-J., Xu, L.-P., Ren, H.-Y., Lai, Y.-R., Liu, D.-H., Liu, L., Sun, Z.-M., Bin Wu, Y.-, Wang, X., et al. (2019). Comparison of outcomes after human leukocyte antigen-matched and haploidentical hematopoietic stem-cell transplantation for multiple myeloma.Chin Med J (Engl).
Mo, X.-D., Zhang, X.-H., Xu, L.-P., Wang, Y., Yan, C.-H., Chen, H., Chen, Y.-H., Han, W., Wang, F.-R., Wang, J.-Z., et al. (2019). Corrigendum to 'Interferon α: A potentially effective treatment for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation' [Biology of Blood and Marrow Transplantation 21/11 (2015) 19.Biol Blood Marrow Transplant.
Mo, X.-D., Zhang, X.-H., Xu, L.-P., Wang, Y., Yan, C.-H., Chen, H., Chen, Y.-H., Han, W., Wang, F.-R., Wang, J.-Z., et al. (2019). Corrigendum to 'Interferon-α is effective for treatment of minimal residual disease in patients with acute leukemia after allogeneic hematopoietic stem cell transplantation: results of a registry study' [Biology of Blood and Marrow Transplantation 23/8 (.Biol Blood Marrow Transplant.
Yan, C.-H., Liu, Q.-F., Wu, D.-P., Zhang, X., Xu, L.-P., Zhang, X.-H., Wang, Y., Huang, H., Bai, H., Huang, F., et al. (2019). Corrigendum to 'Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus host disease guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractor.Biol Blood Marrow Transplant.
Han, T.-T., Xu, L.-P., Liu, D.-H., Liu, K.-Y., Fu, H.-X., Zhao, X.-Y., Zhao, X.-S., and Huang, X.-J. (2013). Cytomegalovirus is a potential risk factor for late-onset hemorrhagic cystitis following allogeneic hematopoietic stem cell transplantation.Am J Hematol.
F
Guo, Z.-P., Wang, T., Xu, L.-P., Zhang, X.-H., Wang, Y., Huang, X.-J., and Chang, Y.-J. (2016). Factors affecting the CD34(+) cell yields from the second donations of healthy donors: The steady-state lymphocyte count is a good predictive factor.Transfus Apher Sci.
Chen, Y., Huang, X.-J., Wang, Y., Liu, K.-Y., Chen, H., Chen, Y.-H., Zhang, X.-H., Wang, F.-R., Han, W., Wang, J.-Z., et al. (2015). Febrile reaction associated with the infusion of haploidentical peripheral blood stem cells: incidence, clinical features, and risk factors.Transfusion.
Zhao, X.-Y., Pei, X.-Y., Chang, Y.-J., Yu, X.-X., Xu, L.-P., Wang, Y., Zhang, X.-H., Liu, K.-Y., and Huang, X.-J. (2019). First-line therapy with donor-derived HCMV-specific T cells reduces persistent HCMV infection by promoting antiviral immunity after allogenic stem cell transplantation.Clin Infect Dis.
Zhang, Y.-Y., Mo, X.-D., Zhang, X.-H., Xu, L.-P., Wang, Y., Yan, C.-H., Chen, H., Chen, Y.-H., Han, W., Wang, F.-R., et al. (2019). FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients.Bone Marrow Transplant.
Zeng, Q.-Z., Zhang, Y.-Y., Wu, Y.-J., Zhang, Z.-Y., Zhang, J.-N., Fu, H.-X., Wang, J.-Z., Wang, F.-R., Yan, C.-H., Mo, X.-D., et al. (2020). Frequency, risk factors and outcome of active tuberculosis following allogeneic hematopoietic stem cell transplantation.Biol Blood Marrow Transplant.

Pages